Standpoint Research Upgrades Teva Pharma (TEVA) to Buy
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $36.77 +0.68%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Standpoint Research upgraded Teva Pharma (NYSE: TEVA) from Hold to Buy.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $61.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) PT Raised to $42 at Barclays
- RBC Capital Upgrades LTC Properties (LTC) to Outperform
- Canaccord Upgrades HLS Therapeutics (HLS:CN) (HLTRF) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
Standpoint ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
